Even though there are several biosimilars for the best-selling drug in the world, Humira, and they've been on the market in the European Union since 2018, American patients must wait another two years for them to be available here due to the manufacturer's aggressive patent thicket strategy of overlapping and late-filed patents.
Discussing delays in biosimilar availability due to patent strategies.
Share
More from Susan Collins
I increased by 17% the budget for the independent Office of Inspector General.
I think what happened is far too many ICE officers were hired and deployed without adequate vetting and training. But let us not forget the important work that ICE does, which is why it should be reformed and not abolished, as Troy has…
I believe that we should create a commission of independent financial experts to give us advice on what should be done.
Other voices in this conversation
